MK-2060 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
End-Stage Renal Disease
Conditions
End-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic
Trial Timeline
Sep 17, 2021 → Feb 13, 2025
NCT ID
NCT05027074About MK-2060 + Placebo
MK-2060 + Placebo is a phase 2 stage product being developed by Merck for End-Stage Renal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05027074. Target conditions include End-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06582602 | Phase 1 | Completed |
| NCT05769595 | Phase 1 | Completed |
| NCT06843993 | Phase 1 | Completed |
| NCT05656040 | Phase 1 | Completed |
| NCT05027074 | Phase 2 | Completed |
| NCT03873038 | Phase 1 | Completed |
Competing Products
20 competing products in End-Stage Renal Disease